- Home
- CBZ vs AKRO Comparison
CBZ vs AKRO Comparison
Compare CBZ & AKRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CBZ
- AKRO
- Stock Information
- Founded
- CBZ 1987
- AKRO 2017
- Country
- CBZ United States
- AKRO United States
- Employees
- CBZ N/A
- AKRO N/A
- Industry
- CBZ Business Services
- AKRO Biotechnology: Pharmaceutical Preparations
- Sector
- CBZ Consumer Discretionary
- AKRO Health Care
- Exchange
- CBZ Nasdaq
- AKRO Nasdaq
- Market Cap
- CBZ 3.5B
- AKRO 3.6B
- IPO Year
- CBZ N/A
- AKRO 2019
- Fundamental
- Price
- CBZ $54.91
- AKRO $46.20
- Analyst Decision
- CBZ
- AKRO Strong Buy
- Analyst Count
- CBZ 0
- AKRO 8
- Target Price
- CBZ N/A
- AKRO $80.38
- AVG Volume (30 Days)
- CBZ 579.9K
- AKRO 978.3K
- Earning Date
- CBZ 10-28-2025
- AKRO 11-07-2025
- Dividend Yield
- CBZ N/A
- AKRO N/A
- EPS Growth
- CBZ N/A
- AKRO N/A
- EPS
- CBZ 1.84
- AKRO N/A
- Revenue
- CBZ $2,420,673,000.00
- AKRO N/A
- Revenue This Year
- CBZ $56.99
- AKRO N/A
- Revenue Next Year
- CBZ $5.51
- AKRO N/A
- P/E Ratio
- CBZ $30.84
- AKRO N/A
- Revenue Growth
- CBZ 46.49
- AKRO N/A
- 52 Week Low
- CBZ $53.92
- AKRO $21.34
- 52 Week High
- CBZ $90.13
- AKRO $58.40
- Technical
- Relative Strength Index (RSI)
- CBZ 34.15
- AKRO 51.07
- Support Level
- CBZ $53.92
- AKRO $41.80
- Resistance Level
- CBZ $57.51
- AKRO $45.44
- Average True Range (ATR)
- CBZ 2.06
- AKRO 1.97
- MACD
- CBZ -0.29
- AKRO 0.06
- Stochastic Oscillator
- CBZ 9.02
- AKRO 74.58
About CBZ CBIZ Inc.
CBIZ Inc through its subsidiaries provides professional services advisors to middle-market businesses and organizations nationwide. Its business units have been aggregated into three practice groups: Financial Services, Benefits and Insurance Services, and National Practices. The company provides its services to various industries such as Banking & Financial Services, Commercial Real Estate, Construction, Health Care Manufacturing & Distribution NFP & Education, Private Client Services, Professional Services, Public Sector, and Technology & Life Sciences. It derives the majority of its revenues from the Financial Services segment and geographically from the United States.
About AKRO Akero Therapeutics Inc.
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis.